Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)’s share price rose 0% during mid-day trading on Tuesday . The stock traded as high as $24.55 and last traded at $23.62. Approximately 788,782 shares changed hands during trading, a decline of 28% from the average daily volume of 1,090,230 shares. The stock had previously closed at $23.61.

ADMS has been the topic of several research analyst reports. Noble Financial reiterated a “buy” rating and set a $33.00 price target on shares of Adamas Pharmaceuticals in a research report on Friday, September 29th. BidaskClub upgraded Adamas Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 23rd. Mizuho reiterated a “buy” rating and set a $26.00 price target on shares of Adamas Pharmaceuticals in a research report on Tuesday, September 5th. Piper Jaffray Companies reiterated an “overweight” rating and set a $30.00 price target on shares of Adamas Pharmaceuticals in a research report on Friday, September 1st. They noted that the move was a valuation call. Finally, Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, September 21st. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. Adamas Pharmaceuticals currently has an average rating of “Buy” and an average target price of $39.50.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.81) by ($0.12). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.03 million. The firm’s revenue for the quarter was down 90.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.78) earnings per share.

Several hedge funds have recently bought and sold shares of ADMS. Parametric Portfolio Associates LLC lifted its stake in shares of Adamas Pharmaceuticals by 153.3% in the 1st quarter. Parametric Portfolio Associates LLC now owns 111,788 shares of the specialty pharmaceutical company’s stock valued at $1,956,000 after purchasing an additional 67,654 shares during the period. Vanguard Group Inc. increased its position in shares of Adamas Pharmaceuticals by 10.3% in the 1st quarter. Vanguard Group Inc. now owns 716,419 shares of the specialty pharmaceutical company’s stock valued at $12,537,000 after buying an additional 66,825 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Adamas Pharmaceuticals by 212.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 60,897 shares of the specialty pharmaceutical company’s stock valued at $1,066,000 after buying an additional 41,436 shares in the last quarter. Fisher Asset Management LLC bought a new stake in shares of Adamas Pharmaceuticals in the 3rd quarter valued at $773,000. Finally, Citadel Advisors LLC bought a new stake in shares of Adamas Pharmaceuticals in the 2nd quarter valued at $606,000. 71.95% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Adamas Pharmaceuticals, Inc. (ADMS) Stock Price Up 0%” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.watchlistnews.com/adamas-pharmaceuticals-inc-adms-stock-price-up-0/1673578.html.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.